Howe & Rusling Inc. Sells 3,950 Shares of Stryker Co. (NYSE:SYK)

Howe & Rusling Inc. decreased its stake in Stryker Co. (NYSE:SYK) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,770 shares of the medical technology company’s stock after selling 3,950 shares during the quarter. Howe & Rusling Inc.’s holdings in Stryker were worth $11,079,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker in the fourth quarter worth $25,000. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. increased its stake in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker during the fourth quarter worth $30,000. Finally, BankPlus Trust Department acquired a new position in shares of Stryker during the fourth quarter worth $33,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $367.34 on Thursday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business has a 50 day simple moving average of $384.74 and a 200-day simple moving average of $374.29. The stock has a market capitalization of $140.17 billion, a PE ratio of 47.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business earned $3.46 EPS. Equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SYK. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Royal Bank of Canada upped their price objective on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Canaccord Genuity Group boosted their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.